CB

Colin Beatty

On the record
Represented by:
Share profile 
Link:
Bio
Edit

Colin Beatty has made a highly successful career out of questioning the healthcare status quo — identifying some of the industry’s most insidious, systemic shortcomings and coming up with innovative solutions to address them. Despite a successful, decade-plus career as a healthcare industry consultant, when a personal tragedy struck Colin and his family in 2011, he felt compelled to take action. Having seen first hand the enormous shortcomings of modern addiction care, Colin was determined to develop an alternative. At the core of Colin’s vision was a system that treated its patients as people — individuals with unique physiological, psychological, and socioeconomic circumstances that must be understood and taken into account in order to treat them effectively. In 2015, Colin brought this vision to life with the founding of Column Health — a non-traditional outpatient facility for the treatment of substance use disorders, which utilizes a holistic, data-driven, biopsychosocial model of care to improve patient outcomes. Despite its novelty, it didn’t take long for this new approach to prove successful. Over just seven years, Column Health grew from just a single facility into 11 in 2022. This runaway success led Column Health to be acquired by Brightview Health in August of that year. Now, Colin is looking to bring this same innovative, integrated, tech-enabled approach to the nascent field of psychedelic assisted treatment (PAT) — with the primary aim of helping some of the tens of millions of Americans currently living with these conditions. Colin's latest PAT startup is currently in stealth mode.

Employment
Sign up to view all
  • Showcase your professional journey! Share your employment history to highlight your industry experience and achievements, making you a sought-after expert.

  • Future of Psychedelic FDA Approval: Insights from Column Health CEO
    Colin highlights regulatory and societal challenges, noting psychedelics' Schedule I classification. He believes a strong medical model is crucial for approval. "Patients may miss out on life-changing therapies." Large-scale trials and policy reforms are key to future approvals.